Search clinical trials for: Budesonide/formoterol pMDI

Total 1032 results

AstraZeneca

Completed

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

Asthma

Croatia
Government Medical College, Bhavnagar

Completed

Controller Medications in the Management of Bronchial Asthma

Moderate to Severe Persistent Bronchial Asthma

India
AstraZeneca

Completed

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

COPD Method Evaluation | Chronic Obstructive Pulmonary Disease Method Evaluation

United Kingdom, Sweden
AstraZeneca

Completed

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler (REALITY)

Perception of Physicians & Patients of AMD
AstraZeneca

Completed

PreAsthmaControl (PAC)

Asthma

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
Medical University of Lodz

Completed

Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma

Asthma

Poland
Chiesi Farmaceutici S.p.A.

Completed

Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma

Asthma

United Kingdom
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
AstraZeneca

Completed

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

Asthma

Malaysia
AstraZeneca

Completed

Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Mundipharma Research Limited

Completed

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

Asthma

Poland, Bulgaria, Romania, India, Hungary
Sunovion

Completed

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
Brigham and Women's Hospital

Completed

Replication of the D58 Asthma Trial in Healthcare Claims Data

Asthma

United States
Sunovion

Completed

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
AstraZeneca

Recruiting

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (ATHLOS)

Chronic Obstructive Pulmonary Disease

Germany, Spain, United States, China, Korea, Republic of, Argentina, United Kingdom, Canada
AstraZeneca

Completed

Pulmicort Asthma Prevention (Post-PAC)

Asthma

Denmark
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
AstraZeneca

Completed

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Asthma | Severe Eosinophilic Asthma

France, Germany, Italy, United Kingdom
AstraZeneca

Completed

Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.

Chronic Obstructive Pulmonary Disease, COPD

Sweden, France, Germany, Hungary, Poland, Canada, Australia, Slovakia, Spain
Chiesi Farmaceutici S.p.A.

Completed

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) (FLASH)

Asthma

United States
University Hospital, Antwerp
AstraZeneca

Completed

Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Chronic Obstructive Pulmonary Disease

Belgium
Novartis Pharmaceuticals

Withdrawn

Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics

Asthma

Turkey
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Completed

Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT (Alloforb)

Obstructive Airway Disease

France
Eurofarma Laboratorios S.A.

Completed

A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma (CAINAS)

ASTHMA

Brazil
AstraZeneca

Completed

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Asthma

Netherlands
Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (DENALI)

Asthma

United States, Germany, Ukraine, Serbia, Czechia, Argentina, Slovakia
Second Affiliated Hospital, School of Medicine,...
Tongji Hospital; Shenzhen People's Hospital; China-Japan Friendship Hospital; Central... and other collaborators

Recruiting

The Efficacy of Budesonide/Formoterol in Cough Variant Asthma

Cough Variant Asthma

China
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca

Completed

Atlantis Symbicort

Asthma
AstraZeneca

Completed

Symbicort Onset of Action 1

Asthma
Sunovion

Completed

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Reig Jofre Group

Completed

Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg

Allergy

South Africa
Hat Yai Medical Education Center

Completed

Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma

Asthma

Thailand
Orion Corporation, Orion Pharma

Terminated

Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway (BufoSwitch)

Asthma | COPD

Norway
Brigham and Women's Hospital
AstraZeneca

Terminated

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo (AZCO)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Zhujiang Hospital

Unknown

Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients

Bronchial Asthma

China
Eurofarma Laboratorios S.A.

Completed

A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma (UNIK)

Asthma

Brazil
AstraZeneca

Completed

SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma

Asthma

Belgium, Luxembourg
AstraZeneca

Completed

SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults

Asthma

France
GlaxoSmithKline

Completed

A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma

Asthma

Argentina
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Hat Yai Medical Education Center

Completed

As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

Asthma

Thailand
AstraZeneca

Completed

A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

Asthma

Sweden, France, United Kingdom, Germany, Denmark, Spain
Assistance Publique - Hôpitaux de Paris

Terminated

Protective Role of Inhaled Steroids for Covid-19 Infection (INHASCO)

Covid-19 Infection | Hospitalization in Respiratory Disease Department

France
Istituto per la Ricerca e l'Innovazione Biomedica

Completed

The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma

Asthma

Italy
Shanghai University of Traditional Chinese Medicine

Unknown

Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.

Cough Variant Asthma

China

3

Subscribe